The use of intralesional recombinant human epidermal growth factor (rhEGF) in advanced diabetic foot ulcers in South Africa

The use of intralesional recombinant human epidermal growth factor (rhEGF) in advanced diabetic foot ulcers in South Africa

Treatment of complex diabetic foot ulcers (DFU) with intra- and perilesional injection of recombinant human epidermal growth factor (rhEGF) has been safe and effective in clinical trials. Here, we report results on the efficacy and safety of this treatment in South Africa.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Wound healing southern Africa 2023-06, Vol.16 (1), p.24
Hauptverfasser: Mothabeng, T G, Ngcobo, T K, Singh, N, Deprés, S C, Valdés, MA, AD Tuero Iglesias, Minkova, AB, Buxadó, JA, JE Baldomero, del Río Martín, A, González, VLM
Format: Artikel
Sprache:eng
Schlagworte:
Clinical outcomes
Diabetes
Epidermal growth factor
Foot diseases
Leg ulcers
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of complex diabetic foot ulcers (DFU) with intra- and perilesional injection of recombinant human epidermal growth factor (rhEGF) has been safe and effective in clinical trials. Here, we report results on the efficacy and safety of this treatment in South Africa.
ISSN:1998-8885
2076-8893